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Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in
the Lumen of Human Intracranial Aneurysms
Nohra Chalouhi, MD; Pascal Jabbour, MD; Mario Zanaty, MD; Robert M. Starke, MD; James Torner, MD; Daichi Nakagawa, MD;
David M. Hasan, MD
Background-—Aspirin is a promising medical therapy for the prevention of intracranial aneurysm (IA) rupture. Recently, we found
that men have a better response to aspirin than women. The purpose of this study was to determine whether a sex differential
exists in the level of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in the lumen of human IAs.
Methods and Results-—Consecutive patients undergoing coiling or stent-assisted coiling for a saccular IA at our institution
were enrolled. Two samples (A and B) were collected from IA lumens, and the plasma level of 15-PGDH was measured using
an ELISA-based method. The study included 38 patients, with 20 women and 18 men. Women and men were comparable on
baseline characteristics. The mean plasma concentration of 15-PGDH did not differ statistically between sample A (62.816.2
ng/mL) and sample B (61.817.9 ng/mL; 95% conﬁdence interval 6.6 to 9.4). The mean plasma concentration of 15-PGDH
in IA lumens of samples A and B was signiﬁcantly higher in men (73.813.5 ng/mL) than women (49.67.8 ng/mL;
P<0.0001).
Conclusions-—Higher enzyme levels of 15-PGDH exist in the lumen of IAs of men compared with women. This observation could
explain why aspirin confers better protection against IA rupture in men than in women. The susceptibility of an individual to aspirin
may differ according to the level of 15-PGDH. ( J Am Heart Assoc. 2017;6:e006639. DOI: 10.1161/JAHA.117.006639.)
Key Words: aneurysm • inﬂammation • sex
P rostaglandins are eicosanoids derived from arachidonicacid through the cyclooxygenase (COX) pathway and
mediate several pathogenic mechanisms, including the inﬂam-
matory response.1 COX-1 is expressed constitutively in most
cells, whereas COX-2 is induced by inﬂammatory stimuli.
Prostaglandin E2, which plays an important role in the patho-
genesis of intracranial aneurysms (IAs),2 is produced by the
sequential enzymatic activity ofCOX-1orCOX-2, followedby that
of prostaglandin E synthase. The levels of prostaglandin E2 and
other prostaglandins are regulated not only by their synthesis
but also by their degradation. As such, 15-hydroxyprostaglandin
dehydrogenase (15-PGDH) is the key enzyme responsible for the
biological inactivation of prostaglandins by converting them to
the corresponding 15-keto derivatives.1 15-PGDH is being
increasingly recognized as a key protective enzyme in several
inﬂammatory and neoplastic disease processes.3,4
Our group and others have shown that different constituents
of the inﬂammatory reaction play a major role in IA formation
and rupture.5,6 We have also found, in both experimental and
human studies, that aspirin, through its anti-inﬂammatory
properties, decreases the risk of IA rupture.7–9 Furthermore,
in a recent study, we reported that aspirin inhibits IA rupture
more efﬁciently in men than women.10 The sex-differential
action of aspirin was reproduced in mice, where higher levels of
15-PGDHwere found in cerebral arteries ofmalemice compared
with femalemice. More important, themodulation of the activity
of 15-PGDH resulted in the reversal of the sex-differential
response in mice, indicating that this enzyme may play a role in
mediating the protective effects of aspirin against IA rupture.10
In the present study, we aimed to determine whether a sex
differential exists in the level of 15-PGDH in the lumen of
human IAs.
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Methods
Study Population
The study protocol was approved by the University of Iowa
(Iowa City) Institutional Review Board, and enrolled subjects
gave informed consent. Consecutive patients undergoing
coiling or stent-assisted coiling for a saccular IA at the
Department of Neurosurgery at the University of Iowa Hospitals
and Clinics between January and June 2016 were enrolled. This
included patients with unruptured aneurysms treated electively
or those treated in the setting of subarachnoid hemorrhage.
Patients with fusiform aneurysms, pseudoaneurysms, and
extracranial aneurysms and those taking steroids or receiving
immunosuppressant therapy were excluded.
Sampling
The technique for intraluminal blood sampling has been
previously described.11 Brieﬂy, after femoral arterial access is
obtained, a sheath is inserted and a guiding catheter is navigated
into the target vessel. A microcatheter is then advanced over a
micro–guide wire and positioned inside the aneurysm sac. Two
samples (A and B) are collected from each aneurysm lumen
before stent or coil deployment, with a total of 3 mL of blood.
Blood is subsequently centrifuged, and the plasma is immedi-
ately stored at80°C. The plasma concentration of 15-PGDH is
measured in each sample using ELISA kits.
Statistical Analysis
Data are presented as mean and SD for continuous variables
and as frequency for categorical variables. The equivalence
test was conducted using 2 1-sided tests to conﬁrm that the
levels of 15-PGDH were similar between samples A and B.
Subsequently, mean 15-PGDH concentrations in samples A+B
were compared between men and women using a nonpara-
metric test (Mann-Whitney U test) because levels of 15-PGDH
were not normally distributed. Correlation between levels of
15-PGDH and age/aneurysm size was assessed using the
Spearman correlation coefﬁcient (r). P≤0.05 was considered
statistically signiﬁcant.
Results
The study included 38 patients, of which 20 were women and
18 were men. Age was 53.813.0 years on average in the
cohort. Mean aneurysm size was 8.67.1 mm. Fourteen
patients (37%) were treated in the setting of subarachnoid
hemorrhage.
Women and men were comparable on baseline character-
istics. Mean age was 54.013.2 years in the female group
and 53.513.4 years in the male group (P=0.9). Mean
aneurysm size was 9.68.9 mm in women versus
7.44.3 mm in men (P=0.4). Of 20 women, 7 (35%) and 7
of 18 men (39%) had ruptured aneurysms (P=0.8). Of 20
women, 2 (10%) were taking aspirin long-term versus 5 of 18
men (28%; P=0.2). The 2 groups did not differ on aneurysm
location (P=0.7) (Table).
The mean plasma concentration of 15-PGDH was
62.816.2 ng/mL in sample A and 61.817.9 ng/mL in
sample B. Using 2 1-sided tests, the concentrations of 15-
PGDH in samples A and B were statistically similar (95%
conﬁdence interval, 6.6 to 9.4).
The mean plasma concentration of 15-PGDH in IA lumens of
samples A and B was signiﬁcantly higher in men (73.813.5
ng/mL) than women (49.67.8 ng/mL; P<0.0001). There was
no association between 15-PGDH levels and age (r=0.13;
P=0.4) or aneurysm size (r=0.17; P=0.3).
Discussion
The inﬂammatory process in arterial walls is the major force
driving IA formation and rupture.5 This process involves
Table. Location of Treated Aneurysms
Location Women Men
Anterior communicating 4 (20) 7 (38.9)
Basilar 3 (15) 2 (11.1)
Middle cerebral 4 (20) 3 (16.7)
Posterior inferior cerebellar 1 (5) 2 (11.1)
Posterior communicating 2 (10) 2 (11.1)
Carotid terminus 2 (10) 1 (5.6)
Posterior cerebral 1 (5) 0
Carotid cavernous 2 (10) 0
Carotid ophthalmic 1 (5) 1 (5.6)
Total 20 18
Clinical Perspective
What Is New?
• Men have higher levels of 15-hydroxyprostaglandin dehy-
drogenase, a key protective enzyme in inﬂammatory
disorders, in the lumen of intracranial aneurysms than
women.
What Are the Clinical Implications?
• Higher levels of 15-hydroxyprostaglandin dehydrogenase in
men may explain why aspirin confers better protection
against intracranial aneurysm rupture in men versus women.
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several inﬂammatory cells and mediators, including macro-
phages, mast cells, lymphocytes, and various cytokines and
chemokines.6 Although inﬂammation involves primarily the
aneurysm wall, recent reports have demonstrated the ability
to detect inﬂammatory changes in IA lumens.11,12 As such,
our group has shown a local increase of the concentration of
chemokines and chemoattractant cytokines in the lumen of
human IAs compared with peripheral arterial blood, suggest-
ing active recruitment of inﬂammatory cells into aneurysm
walls.11 In another study, there was a signiﬁcant positive
correlation between IA size and the plasma concentration of
granulocyte-monocyte colony-stimulating factor in IA
lumens.12 It is, therefore, possible to study the inﬂammatory
process in IAs by sampling blood safely from aneurysm
lumens during endovascular treatment.
Aspirin has emerged as a potentially promising medical
therapy to prevent IA rupture.7–9 The protective effects of
aspirin were initially reported by Hasan et al13 in a nested
case-control study from the ISUIA (International Study of
Unruptured Intracranial Aneurysms), where frequent aspirin
use (39 weekly to daily) was associated with a signiﬁcant
decrease in the risk of aneurysm rupture. The mechanism
appears to involve the inhibition of COX-2, which is more
prominently expressed in the wall of ruptured than unrup-
tured human IAs.2 As such, in a randomized study, aspirin
therapy was associated with a signiﬁcant decrease in the
expression of inﬂammatory markers, including COX-2 in
human IA walls compared with controls.8 A recent analysis
of the ISUIA data revealed that aspirin decreased the risk of
IA rupture more signiﬁcantly in men than in women,
suggesting a sex-differential response.10 Likewise, male
mice taking aspirin had a lower rate of IA rupture and
higher levels of 15-PGDH, a prostaglandin-degrading enzyme
that physiologically antagonizes COX-2, than female mice
taking aspirin. Interestingly, the addition of 15-PGDH agonist
in female mice led to the reversal of the observed
differential sex response to aspirin.10 These ﬁndings raised
the question about whether women may have lower levels of
15-PGDH, an enzyme that may mediate the protective
effects of aspirin against IA rupture.
The present study brings evidence that women do have
remarkably lower enzyme levels of 15-PGDH in IA lumens than
men. It may be possible that the susceptibility to aspirin may
differ according to the level of 15-PGDH, which explains why
men had better protection against IA rupture than women in
ISUIA. This observation is similar to the protective effects of
aspirin in colorectal cancer, where aspirin is associated with a
lower incidence of colorectal cancers arising in association
with high 15-PGDH expression, but not with low 15-PGDH
expression.14 As such, 15-PGDH level in IA lumens and walls
may serve as a biomarker that may predict stronger beneﬁt
from aspirin.
Limitations
We did not compare the levels of 15-PGDH in the walls of IAs
between women and men. Such a study is underway, but we
foresee several years of patient recruitment to gather a large
enough sample because endovascular therapy is signiﬁcantly
more used than microsurgical clipping in most centers,
including ours. Because of the small sample size of our study,
we could not test the effect of long-term aspirin use on the
levels of 15-PGDH. It would be interesting to longitudinally
observe the risk of IA rupture in patients taking aspirin and
correlate this with the intraluminal enzyme level of 15-PGDH.
Conclusions
The present study shows consistently higher enzyme levels of
15-PGDH in IA lumens of men compared with women. This
observation could explain the sex-differential response to
aspirin in preventing IA rupture. It may be possible that the
susceptibility to aspirin may differ according to the level of 15-
PGDH.
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